ArriVent BioPharma, Inc. (AVBP) shareholders
Close on Nov 17, 2026Market cap $527.10MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| HHLR Advisors, Ltd. Joint filing with Hillhouse Investment Management, Ltd. (13.40%) | 4,484,672 | 13.40% | 13G (passive) | Sep 30, 2024 |
| Infinitum Cayman Master, Ltd. Joint filing with Infinitum Asset Management, LLC (9.90%), Infinitum Partners GP, LLC (9.90%) | 4,123,923 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Hillhouse Investment Management, Ltd. | 3,929,117 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| Infinitum Cayman Master, Ltd. (Fund) Joint filing with Infinitum Asset Management, LLC (9.90%), Infinitum Partners GP, LLC (9.90%) | 3,418,923 | 9.90% | 13G (passive) | May 1, 2025 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (9.90%), Averill Master Fund, Ltd. (8.70%) | 3,412,788 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 3,182,080 | 6.80% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (6.80%) | 3,016,132 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
| Orbimed Advisors LLC | 2,875,962 | 5.80% | 13D (active) amendment | Oct 6, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (5.80%) | 2,863,340 | 5.80% | 13G (passive) amendment | Sep 30, 2026 |
| Vivo Opportunity, LLC | 2,472,701 | 5.00% | 13G (passive) | Oct 6, 2026 |
| HBM Healthcare Investments (Cayman) Ltd. | 2,195,014 | 5.40% | 13G (passive) | Oct 8, 2025 |
| Yi Shi Joint filing with LAV Fund VI, L.P. (“LAVVI”) (6.20%) | 2,046,123 | 6.40% | 13G (passive) | Jan 26, 2024 |
| Dr. Maha Katabi (“Katabi”) Joint filing with Sofinnova Venture Partners XI, L.P. (“SVP XI”) (5.10%), Sofinnova Management XI, L.P. (“SM XI LP”) (5.10%) and 2 more | 1,696,752 | 5.10% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AVBP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 4,515,531 | 9.16% | $156.87M | +114,448 | 2.87% |
| Infinitum Asset Management, LLC | 4,438,384 | 9.00% | $154.19M | +289,461 | 15.68% |
| Hhlr Advisors, Ltd. | 3,929,117 | 7.97% | $136.50M | – | 16.40% |
| BlackRock, Inc. | 3,250,396 | 6.59% | $112.92M | +720,095 | 0.00% |
| Orbimed Advisors LLC | 3,027,328 | 6.14% | $105.17M | – | 1.95% |
| FMR LLC | 2,778,959 | 5.64% | $96.54M | −237,173 | 0.00% |
| Octagon Capital Advisors LP | 1,971,054 | 4.00% | $68.47M | – | 6.15% |
| Vanguard Capital Management LLC | 1,774,873 | 3.60% | $61.66M | +245,980 | 0.00% |
| Sofinnova Investments, Inc. | 1,696,752 | 3.44% | $58.95M | – | 3.05% |
| State Street Corp | 1,692,986 | 3.43% | $58.81M | +271,571 | 0.00% |
| Vivo Capital, LLC | 1,682,097 | 3.41% | $58.44M | +796,181 | 5.34% |
| Novo Holdings A/S | 1,500,000 | 3.04% | $52.11M | −442,142 | 3.03% |
| General Catalyst Group Management, LLC | 1,494,786 | 3.03% | $51.93M | – | 27.55% |
| Logos Global Management LP | 1,000,000 | 2.03% | $34.74M | +650,000 | 1.50% |
| Geode Capital Management, LLC | 972,626 | 1.97% | $33.80M | +168,974 | 0.00% |
| D. E. Shaw & Co., Inc. | 872,011 | 1.77% | $30.29M | +503,216 | 0.01% |
| Goldman Sachs Group Inc | 853,723 | 1.73% | $29.66M | +296 | 0.00% |
| HSG Holding Ltd | 663,308 | 1.35% | $23.04M | – | 1.85% |
| Point72 Asset Management, L.P. | 566,796 | 1.15% | $19.69M | −181,399 | 0.02% |
| Millennium Management LLC | 438,664 | 0.89% | $15.24M | +12,741 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 158 | 46M | 93.5% | 36 / 72 | 30 / 15 | 6M | 2M |
| Q1 2026 | 139 | 42M | 85.4% | 35 / 58 | 28 / 17 | 7M | 3M |
| Q4 2025 | 122 | 40M | 81.3% | 30 / 41 | 35 / 14 | 5M | 3M |
| Q3 2025 | 106 | 39M | 78.3% | 18 / 47 | 18 / 11 | 6M | 1M |
| Q2 2025 | 99 | 34M | 68.2% | 26 / 25 | 30 / 9 | 5M | 1M |
| Q1 2025 | 83 | 29M | 59.0% | 15 / 29 | 22 / 11 | 2M | 1M |
| Q4 2024 | 80 | 28M | 57.7% | 24 / 33 | 12 / 11 | 3M | 1M |
| Q3 2024 | 68 | 26M | 52.6% | 17 / 37 | 3 / 2 | 5M | 0M |
| Q2 2024 | 54 | 22M | 43.9% | 12 / 22 | 8 / 11 | 1M | 2M |
| Q1 2024 | 53 | 22M | 44.4% | 53 / 0 | 0 / 0 | 22M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
139 funds held AVBP in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AVBP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 1,439,803 | 2.92% | $43.58M | 0.83% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,338,764 | 2.72% | $46.51M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 984,786 | 2.00% | $34.21M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 880,426 | 1.79% | $30.59M | 0.28% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 414,872 | 0.84% | $12.37M | 0.04% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 397,078 | 0.81% | $13.79M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 350,006 | 0.71% | $12.16M | 0.08% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 324,040 | 0.66% | $9.81M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 298,740 | 0.61% | $8.91M | 0.10% | Jul 31, 2026 |
| iShares Biotechnology ETF | 230,487 | 0.47% | $8.01M | 0.09% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 165,782 | 0.34% | $5.02M | 0.03% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 158,190 | 0.32% | $4.79M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 149,030 | 0.30% | $4.44M | 0.10% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 147,128 | 0.30% | $4.45M | 0.02% | May 31, 2026 |
| iShares Micro-Cap ETF | 127,000 | 0.26% | $4.41M | 0.29% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Stuart Lutzker | President of R&D, Director | 147,744 | 0.30% | Feb 4, 2026 |
| Zhengbin Yao | President and CEO, Director | 613,138 | 1.24% | Feb 4, 2026 |
| Robin LaChapelle | Chief Operating Officer | 570,906 | 1.16% | Nov 2, 2026 |
| Winston Kung | Chief Financial Officer | – | – | Feb 4, 2026 |
| James Paul Kastenmayer | General Counsel | 7,386 | 0.01% | Feb 4, 2026 |
| John Hohneker | Director | – | – | Jun 22, 2026 |
| Chris Nolet | Director | – | – | Jun 22, 2026 |
| Kristine Peterson | Director | – | – | Jun 22, 2026 |
| Merdad Parsey | Director | – | – | Jun 22, 2026 |
| Hhlr Advisors, Ltd. | 10% owner | 3,929,117 | 7.97% | Feb 3, 2026 |
| Hillhouse Investment Management, Ltd. | 10% owner | – | – | Feb 3, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robin LaChapelle Chief Operating Officer | Oct 30, 2026 | Option exercise | +17,648 | $6.24 | $110.05K | 176,429 |
| Robin LaChapelle Chief Operating Officer | Oct 30, 2026 | Option exercise | +1,820 | $2.28 | $4.15K | 158,781 |
| Robin LaChapelle Chief Operating Officer | Oct 30, 2026 | Option exercise | +4,550 | $2.28 | $10.38K | 156,961 |
| Robin LaChapelle Chief Operating Officer | Oct 30, 2026 | Option exercise | +410 | $2.28 | $935 | 152,411 |
| Robin LaChapelle Chief Operating Officer | Oct 30, 2026 | Option exercise | +16,265 | $3.65 | $59.37K | 152,001 |
| Hhlr Advisors, Ltd. 10% owner | Dec 10, 2025 | Sale | −555,555 | $23.37 | $12.98M | 3,929,117 |
| Robin LaChapelle Chief Operating Officer | Jul 11, 2025 | Option exercise | +2,600 | $2.28 | $5.93K | 129,233 |
| Robin LaChapelle Chief Operating Officer | Jul 11, 2025 | Option exercise | +6,503 | $2.28 | $14.83K | 135,736 |
| Robin LaChapelle Chief Operating Officer | Jul 11, 2025 | Option exercise | +2,050 | $2.28 | $4.67K | 126,633 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +2,867 | $2.28 | $6.54K | 102,584 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +2,700 | $6.24 | $16.85K | 99,717 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +7,164 | $2.28 | $16.33K | 109,748 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +12,364 | $3.65 | $45.13K | 124,583 |
| Robin LaChapelle Chief Operating Officer | Sep 19, 2024 | Option exercise | +2,471 | $2.28 | $5.63K | 112,219 |
| Hhlr Advisors, Ltd. 10% owner | Jan 30, 2024 | Conversion | +3,616,041 | – | – | 3,616,041 |
| Hhlr Advisors, Ltd. 10% owner | Jan 30, 2024 | Buy | +555,555 | $18.00 | $10.00M | 4,484,672 |
| Hhlr Advisors, Ltd. 10% owner | Jan 30, 2024 | Conversion | +313,076 | – | – | 3,929,117 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Buy | +222,222 | $18.00 | $4.00M | 1,513,664 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Conversion | +821,827 | – | – | 821,827 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Conversion | +821,827 | – | – | 821,827 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Conversion | +469,615 | – | – | 1,291,442 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Buy | +222,222 | $18.00 | $4.00M | 1,513,664 |
| Carl L. Gordon Director, 10% owner | Jan 30, 2024 | Conversion | +469,615 | – | – | 1,291,442 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Conversion | +821,827 | – | – | 821,827 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Conversion | +821,827 | – | – | 821,827 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Conversion | +469,615 | – | – | 1,291,442 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Conversion | +469,615 | – | – | 1,291,442 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Buy | +222,222 | $18.00 | $4.00M | 1,513,664 |
| OrbiMed Asia GP IV, L.P. Director, 10% owner | Jan 30, 2024 | Buy | +222,222 | $18.00 | $4.00M | 1,513,664 |
| James Healy Director | Jan 30, 2024 | Buy | +444,444 | $18.00 | $8.00M | 1,696,752 |
| James Healy Director | Jan 30, 2024 | Conversion | +1,252,308 | – | – | 1,252,308 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ArriVent BioPharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 206,555 shares on Oct 7, 2026 over the last 90 days.
See a number that looks wrong?